Skip to main content
. 2018 Aug 22;9:884. doi: 10.3389/fphar.2018.00884

Figure 6.

Figure 6

Validation of the abundance of SCMs generated from HILIC column chromatography in AG, RG, and HC groups in Validation phase. (A), 2-Hexenoylcarnitine; (B),1-Methylhistidine; (C), Asymmetric dimethylarginine; (D), 5′-Methylthioadenosine; (E), Butyrylcarnitine; (F), N-Acetylputrescine; (G), Creatinine; (H), Valerylcarnitine; (I), 1-Methyladenosine. *indicates P < 0.05, **indicates P < 0.01, and ***indicates P < 0.001. P < 0.05 indicates statistical significance. SCMs, significantly changed metabolites. Targeted metabolomics analyses was used to validate the abundance of SCMs in Validation phase. The HC, RG, and AG groups in Validation phase included 20, 26, 29 subjects, respectively.